2024
DOI: 10.1016/j.pharmthera.2024.108743
|View full text |Cite
|
Sign up to set email alerts
|

Nutraceuticals target androgen receptor-splice variants (AR-SV) to manage castration resistant prostate cancer (CRPC)

Ashish Tyagi,
Balaji Chandrasekaran,
Vaibhav Shukla
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 112 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?